BrightPath Biotherapeutics Co., Ltd.
4594.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥3,586,276 | ¥4,234,710 | ¥10,261,567 | ¥5,355,292 |
| - Cash | ¥810,470 | ¥1,057,360 | ¥1,530,969 | ¥2,305,026 |
| + Debt | ¥25,000 | ¥112,500 | ¥0 | ¥87,500 |
| Enterprise Value | ¥2,800,806 | ¥3,289,850 | ¥8,730,598 | ¥3,137,766 |
| Revenue | ¥1,133 | ¥72 | ¥5,280 | ¥15,408 |
| % Growth | 1,473.6% | -98.6% | -65.7% | – |
| Gross Profit | ¥1,101 | -¥341 | ¥3,385 | ¥12,091 |
| % Margin | 97.2% | -473.6% | 64.1% | 78.5% |
| EBITDA | -¥1,149,249 | -¥1,165,786 | -¥1,466,952 | -¥1,446,287 |
| % Margin | -101,434.2% | -1,619,147.2% | -27,783.2% | -9,386.6% |
| Net Income | -¥1,151,149 | -¥1,168,082 | -¥1,485,633 | -¥1,484,192 |
| % Margin | -101,601.9% | -1,622,336.1% | -28,137% | -9,632.6% |
| EPS Diluted | -14.12 | -18.21 | -24.9 | -28.55 |
| % Growth | 22.5% | 26.9% | 12.8% | – |
| Operating Cash Flow | -¥1,250,359 | -¥1,156,920 | -¥1,204,401 | -¥1,512,022 |
| Capital Expenditures | -¥1,370 | -¥7,648 | -¥1,760 | -¥17,646 |
| Free Cash Flow | -¥1,251,729 | -¥1,164,568 | -¥1,206,161 | -¥1,529,668 |